Clinical trial · Interventional
Hetrombopag in Promoting Platelet Engraftment After Auto-HSCT in Children With Neuroblastoma
Efficacy and Safety of Hetrombopag in Promoting Platelet Engraftment After Autologous Hematopoietic Stem Cell Transplantation in Children With Neuroblastoma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this clinical trial is to learn if hetrombopag promotes platelet engraftment in neuroblastoma children undergoing autologous hematopoietic stem cell transplantation. The main question it aims to answer is: · Does drug hetrombopag promote platelet engraftment? Participants will take hetrombopag every day for 6 weeks or until platelet \> 100\*10\^9/L.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Autologous Hematopoietic Stem Cell Transplantation | — | UNRESOLVED | — |
| Delayed Platelet Engraftment | — | UNRESOLVED | — |
| Neuroblastoma | Neuroblastoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Hetrombopag | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Experimental group
- interventionNames
- Drug: Hetrombopag
Primary outcomes (1)
- measure
- Accumulated platelet engraftment rate
- timeFrame
- From enrollment to 60 days post-transplant
- description
- Platelet engraftment is defined as a continuous 7-day PLT ≥ 20 × 10\^9/L without platelet infusion.
Secondary outcomes (4)
- measure
- Number of platelet transfusions
- timeFrame
- From enrollment to 60 days post-transplant
- measure
- Time to platelet engraftment
Eligibility
Eligibility (as posted)
- Sex
- All
- Maximum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age\<18 years old; * Diagnosed as neuroblastoma; * ECOG ≤ 2; * First time receiving autologous hematopoietic stem cell transplantation; * The subjects or their legal guardians agree to participate and sign the informed consent form. Exclusion Criteria: * ALT/AST \> 3 ULN, or TBIL \> 1.5 ULN; * Have experienced congestive heart failure, arrhythmia, peripheral arteriovenous thrombosis requiring medication treatment within one year prior to enrollment, or have experienced myocardial infarction or cerebral infarction within three months prior to enrollment; * Suffering from thromboembolic diseases; * Other situations that are not suitable for inclusion in the study determined by researchers.
References
Publications (0)
Data not yet available